1. Home
  2. SLGL vs EVG Comparison

SLGL vs EVG Comparison

Compare SLGL & EVG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sol-Gel Technologies Ltd.

SLGL

Sol-Gel Technologies Ltd.

HOLD

Current Price

$60.00

Market Cap

159.7M

Sector

Health Care

ML Signal

HOLD

Logo Eaton Vance Short Diversified Income Fund Eaton Vance Short Duration Diversified Income Fund of Beneficial Interest

EVG

Eaton Vance Short Diversified Income Fund Eaton Vance Short Duration Diversified Income Fund of Beneficial Interest

HOLD

Current Price

$10.93

Market Cap

148.1M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLGL
EVG
Founded
1997
2005
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
159.7M
148.1M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
SLGL
EVG
Price
$60.00
$10.93
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$110.00
N/A
AVG Volume (30 Days)
23.5K
49.4K
Earning Date
11-20-2025
01-01-0001
Dividend Yield
N/A
8.68%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$18,970,000.00
N/A
Revenue This Year
$122.71
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
62.04
N/A
52 Week Low
$4.02
$9.13
52 Week High
$75.00
$10.86

Technical Indicators

Market Signals
Indicator
SLGL
EVG
Relative Strength Index (RSI) 63.45 45.81
Support Level $48.26 $10.92
Resistance Level $65.17 $10.99
Average True Range (ATR) 7.83 0.06
MACD -0.58 -0.00
Stochastic Oscillator 63.05 16.40

Price Performance

Historical Comparison
SLGL
EVG

About SLGL Sol-Gel Technologies Ltd.

Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.

About EVG Eaton Vance Short Diversified Income Fund Eaton Vance Short Duration Diversified Income Fund of Beneficial Interest

Eaton Vance Short Duration Diversified Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to provide a high level of current income with a secondary objective of seeking capital appreciation to the extent consistent with its primary goal. The portfolio of investments consists of business equipment and services, automotive, cable and satellite television, chemicals and plastics, food products, and other areas.

Share on Social Networks: